Premature ovarian insufficiency (POI) is defined as a loss of ovarian function before the age of 40 years, with a prevalence rate estimated at approximately 1%. It causes infertility and is related to serious long-term health consequences, including reduced life expectancy, increased cardiovascular risk, decreased bone mineral density and neurological disorders. There is currently no effective therapy for POI that is widely available in clinical practice; therefore, the treatment of patients with POI is based on hormone replacement therapy. One of the recent advances in the understanding of the pathophysiology of POI has been the role of microRNAs (miRNAs) and other noncoding RNAs (ncRNAs) in the disease. Moreover, intensive research on human folliculogenesis and reproductive biology has led to the development of novel promising therapeutic strategies with the use of exosomal miRNAs derived from mesenchymal stem cells to restore ovarian function in POI patients. This narrative review focuses on the new studies concerning the role of ncRNAs in the pathogenesis of POI, together with their potential as biomarkers of the disease and targets for therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8430788 | PMC |
| http://dx.doi.org/10.3390/ijms22179336 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The impact of the trigger day progesterone, luteinizing hormone and their interaction on live birth rates in GnRH antagonist cycles.
J Obstet Gynaecol Res
January 2025
Department of Obstetrics and Gynecology, Health Sciences University, Tepecik Education and Research Hospital, Izmir, Turkey.
Aim: This study aims to assess the impacts of various trigger day progesterone (P) and luteinizing hormone (LH) levels on live birth rates (LBRs) in fresh in vitro fertilization (IVF) cycles, considering their elevation from stimulation and premature luteinization.
Methods: This retrospective cohort study included the first ovarian stimulation cycles with GnRH antagonist protocol of 1253 patients who underwent intracytoplasmic sperm injection and fresh embryo transfer at a tertiary clinic's IVF center between 2010 and 2016. Participants were divided into four groups based on trigger day serum P and LH levels, using the 90th percentile thresholds for P (1.
Elevated plasma molybdenum level increases the risk of premature ovarian insufficiency through vascular endothelial injury.
Hum Reprod
January 2025
The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Study Question: Is elevated plasma molybdenum level associated with increased risk for idiopathic premature ovarian insufficiency (POI)?
Summary Answer: Elevated plasma molybdenum level is associated with an increased risk of idiopathic POI through vascular endothelial injury and inhibition of granulosa cell proliferation.
What Is Known Already: Excessive molybdenum exposure has been associated with ovarian oxidative stress in animals but its role in the development of POI remains unknown.
Study Design, Size, Duration: Case-control study of 30 women with idiopathic POI and 31 controls enrolled from August 2018 to May 2019.
Knowledge Mapping of Stem Cell Therapy for Premature Ovarian Insufficiency: A Bibliometric Analysis (2000-2023).
Curr Stem Cell Res Ther
December 2024
Department of Gynecology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University/Beijing Maternal and Child Health Care Hospital, Beijing, China.
Background: Premature Ovarian Failure (POI), a prevalent gynecological, endocrine disease, significantly impairs the reproductive health of women of childbearing age and presents a formidable challenge to clinicians. Until now, there has been a lack of effective treatments to fundamentally improve ovarian function in patients with POI. Stem cell therapy has emerged as a promising treatment in the field of POI, with notable research progress achieved to date.
View Article and Find Full Text PDFEfficacy of concurrent utilization of estradiol valerate and Chinese herbal capsule in managing premature ovarian failure.
Afr J Reprod Health
November 2024
Department of Gynecologic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin,300060 China.
The objective of this study was to examine the efficacy of the concurrent utilization of estradiol valerate and kuntai capsule (a Chinese herbal preparation) in addressing premature ovarian failure (POF) and its ramifications for ovarian hemodynamics and sex hormone levels. A retrospective study of 104 patients with POF was conducted, dividing them into control (n=50) and observation groups (n=54). The control group received estradiol valerate, while the observation group received estradiol valerate and KunTai capsules over 12 weeks.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!